Product Details
1/EA
$ *.**
In Stock1/UN
$ *.**
In StockAdditional Information
| Product Name | Zirabev SF 25 mg/mL 4 mL |
| Active Ingredient | Bevacizumab-bvzr (Biosimilar to Bevacizumab) |
| Mechanism of Action | Inhibits VEGF to prevent tumor angiogenesis and growth |
| Strength | 25 mg/mL |
| Route of Administration | Intravenous (IV) Infusion |
| Common Side Effects | Hypertension, proteinuria, epistaxis, fatigue, gastrointestinal disturbances |
| Serious Risks | Gastrointestinal perforation, severe hemorrhage, thromboembolic events, impaired wound healing |
| Precautions | Discontinue before surgery; monitor blood pressure and renal function |
| Monitoring Parameters | Blood pressure, urine protein, signs of bleeding or thrombosis |
| Dilution Requirements | Dilute in 0.9% sodium chloride before IV administration |
| Storage Conditions | Store at 2°C to 8°C (36°F to 46°F); protect from light; do not freeze or shake |
| Packaging | Single-dose vial |
| Usage | Used in combination with chemotherapy for the treatment of advanced cancers |
Description
Zirabev SF 25 mg/mL is a biosimilar to bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). It is indicated for the treatment of multiple cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and persistent, recurrent, or metastatic cervical cancer. By blocking VEGF, Zirabev disrupts tumor angiogenesis, reducing blood supply to the tumor and inhibiting its growth and metastasis.
Administration is via intravenous infusion, with dosing dependent on the specific cancer type being treated. It is typically given in combination with chemotherapy. The infusion should be administered over a controlled duration to minimize infusion-related reactions. Premedication may be required in certain patients to reduce hypersensitivity risks. Common adverse effects include hypertension, proteinuria, epistaxis, and fatigue.
Patients receiving Zirabev require monitoring for hypertension, proteinuria, and thromboembolic events. Blood pressure should be regularly assessed, and urine protein levels should be measured periodically. The medication should be discontinued prior to elective surgery and resumed only after adequate wound healing.
Frequently Asked Questions (FAQs)
The cost of ZIRABEV SF 25MG/ML 4ML is $$0.00
ZIRABEV SF 25MG/ML 4ML is manufactured by Pfizer.
You can purchase ZIRABEV SF 25MG/ML 4ML on our website at https://cobalt.pipelinemedical.com/product/detail/zirabev-sf-25mg-ml-4ml-665781